T Cell Characteristics Impact Response and Resistance to T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma

The anti-multiple myeloma (MM) activity of teclistamab and talquetamab was evaluated in bone marrow (BM) samples from MM patients. T cell phenotype and function were assessed in BM/peripheral blood samples obtained from MM patients who were treated with these bispecific antibodies.